Dr. Prof Peter Szlosarek

About Dr. Prof Peter Szlosarek

Dr Peter Szlosarek is a Clinical Senior Lecturer and Consultant in Medical Oncology with a PhD in Translational Cancer Medicine from the University of London.
His post-doctoral work has focused on the role of abnormal tumour metabolism and inflammation.
His main clinical interests are in melanoma, lung cancer, and mesothelioma, with emphasis on targeted drugs, metabolic, and immunotherapeutic approaches.
He has expertise in the treatment of lung cancer, melanoma, and mesothelioma.
He has served as a reviewer for national and international journals.
He has worked as a grant reviewer for national and international funding agencies.
Professor Szlosarek graduated from King’s College, London in 1994 with degrees in Pharmacology, Medicine, and Surgery.
He was awarded the Pharmacology and Therapeutics Intercalated BSc Prize and the Legg Prize in Surgical Pathology.
He obtained the MRCP in 1997 and trained in Medical Oncology at St. George’s, Guy’s, and St. Bartholomew’s Hospitals.
After a substantive NHS Oncology Consultant post, he rejoined the Barts Cancer Institute as a Principal Investigator in 2008.
His translational lab program focuses on tumour metabolism and inflammation, aligning closely with his clinical research interests.
He is actively involved in undergraduate and postgraduate education.
He has published extensively in journals such as Cancer Research, Clinical Cancer Research, Lancet Oncology, and Journal of Clinical Oncology.
His research has been presented at international conferences, with invited lectures in the US, Europe, and Asia.

Conditions treated by Dr Prof. Peter Szlosarek

All conditions related to Oncoplastic Surgery
Lung Cancer
Melanoma
Skin Cancer

Area of Interest

Medical Oncology

Qualification

Graduated in Medicine, Surgery, and Pharmacology from King’s College, London (1994)
Obtained MRCP (Membership of the Royal College of Physicians) in 1997.
PhD in Translational Cancer Medicine/ Cancer Biology from the University of London.

Work Experiences

He has trained in medical oncology at St. George’s, Guy’s and St. Bartholomew’s Hospitals in London.
Has also served as a Consultant in Medical Oncology and Clinical Senior Lecturer at Barts Cancer Institute / St. Bartholomew’s Hospital.
He returned to Barts Cancer Institute in 2008 as a Principal Investigator to lead translational research in tumour metabolism and inflammation related to lung, skin, and mesothelioma cancers.

Global Team of Board Certified Surgeons and Medical Specialists
Written Second Opinion report delivered within 5 days
Option to avail the Video Consultation with the Lead Doctor of the board

Access Our most trusted Medical Second Opinion

Telemedicine Doctors

Do you know?

You can book a video consultation with Dr. Prof Peter Szlosarek on our platform

Consult Online

CERTIFICATIONS (1)

MEMBERSHIPS (5)

Member of the Royal College of Physicians (RCP)
NCRI Mesothelioma Subgroup (Member)
American Association for Cancer Research (Member)
European Organisation for Research and Treatment of Cancer (Member)
American Society of Clinical Oncology (Member)

RESEARCH PAPERS AND PUBLICATIONS (4)

Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers. J Clin Onc (2017) 35 (16):1778-785. PMID: 28388291
Arginine Deprivation with Pegylated Arginine Deiminase in Patients with ASS1-Deficient Malignant Pleural Mesothelioma: A Randomised Clinical Trial. JAMA Oncol (2017)3(1):58-60. PMID: 27584578
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res (2014) 74(3):896-907. PMID: 24285724
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 12(23):7126-31. PMID: 17145837

Share Your Experience about Dr. Prof Peter Szlosarek

Write Your Review

PROCEDURES

Chemotherapy
Hysterectomy
Immunotherapy
Lung Cancer Treatment
Skin Cancer Treatment

FREQUENTLY ASKED QUESTIONS

Is Dr. Prof Peter Szlosarek doing teleconsultation on the MediGence platform?

Dr. Prof Peter Szlosarek is available to teleconsult on the MediGence platform.

How long is the consultation?

The consultation can last from 15 to 30 minutes. It may exceed the estimated time, depending on the patient’s queries and the doctor's medical suggestions.

How soon can the consultation be organised?

We have Medical specialists and board-certified doctors on our panel of doctors. The consultation will be organised within 24 to 48 hours or based on the availability of the doctor and the patient.

Is a follow-up consultation included in the consultation price?

No, the follow-up consultation fee is not included in the consultation price. The patient will be required to re-book the consultation.

How do I share my medical record with the doctor for review?

The option to share your medical records is available between the steps of the form provided to you on the website.

Can I book my procedure with the doctor after the consultation?

Yes. If you are satisfied with the consultation, you can proceed with treatment packages tailored to your diagnosis, assisted by our case managers.

Can you get an estimate for the procedure?

Yes. The cost estimate will be provided to you by our case manager, including the doctor’s opinion, the cost estimate, and crucial information about travelling to your medical destination.

FAQ's Related to Medical Oncologist

What does a Medical Oncologist do?

A Medical Oncologist is a doctor who specializes in diagnosing and treating cancer using therapies such as chemotherapy, immunotherapy, targeted therapy, and hormone therapy.

How is a Clinical Oncologist different from a Medical Oncologist?

A Medical Oncologist focuses on systemic treatments (like chemotherapy and targeted drugs), whereas a Clinical Oncologist may also provide radiotherapy in addition to systemic therapy.

What conditions does a Medical Oncologist commonly treat?

They typically treat cancers of the breast, lung, prostate, bowel, ovary, skin (melanoma), and other solid tumours, depending on their area of specialisation.

When should I see a Medical Oncologist?

You should see a Medical Oncologist when you are diagnosed with cancer, require treatment planning, or need expert advice on systemic therapies and clinical trial options.

What treatments can be provided by a Medical Oncologist?

They provide treatments such as chemotherapy, immunotherapy, hormone therapy, biological therapy, targeted therapy, and supportive care for managing side effects.

Do Medical Oncologists participate in research and clinical trials?

Yes, many Medical Oncologists are actively involved in research, leading clinical trials, and developing new therapies to improve cancer treatment outcomes.

Welcome To MediGence

Your Notifications